DE2329298A1 - Naphtalinderivate und deren anwendung als neue medikamente - Google Patents
Naphtalinderivate und deren anwendung als neue medikamenteInfo
- Publication number
- DE2329298A1 DE2329298A1 DE19732329298 DE2329298A DE2329298A1 DE 2329298 A1 DE2329298 A1 DE 2329298A1 DE 19732329298 DE19732329298 DE 19732329298 DE 2329298 A DE2329298 A DE 2329298A DE 2329298 A1 DE2329298 A1 DE 2329298A1
- Authority
- DE
- Germany
- Prior art keywords
- naphthalene
- derivatives
- amino
- formula
- namely
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical class C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 title description 9
- 239000002547 new drug Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 5
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 150000002790 naphthalenes Chemical class 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 235000005985 organic acids Nutrition 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- DMDOTRUOIVBPSF-UHFFFAOYSA-N naphthalene;hydrochloride Chemical compound Cl.C1=CC=CC2=CC=CC=C21 DMDOTRUOIVBPSF-UHFFFAOYSA-N 0.000 claims 2
- 230000001760 anti-analgesic effect Effects 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- 230000008018 melting Effects 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- -1 naphthalene chlorohydrate Chemical compound 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7220746A FR2187319B1 (enrdf_load_stackoverflow) | 1972-06-09 | 1972-06-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2329298A1 true DE2329298A1 (de) | 1973-12-20 |
Family
ID=9099917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19732329298 Pending DE2329298A1 (de) | 1972-06-09 | 1973-06-08 | Naphtalinderivate und deren anwendung als neue medikamente |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JPS4969645A (enrdf_load_stackoverflow) |
| BE (1) | BE800510A (enrdf_load_stackoverflow) |
| CH (1) | CH573897A5 (enrdf_load_stackoverflow) |
| DE (1) | DE2329298A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2187319B1 (enrdf_load_stackoverflow) |
| GB (1) | GB1395124A (enrdf_load_stackoverflow) |
| NL (1) | NL7308001A (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003104178A1 (en) * | 2002-06-07 | 2003-12-18 | Cortical Pty Ltd | Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (mif) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1962497C3 (de) * | 1969-12-12 | 1979-09-20 | C.H. Boehringer Sohn, 6507 Ingelheim | Naphthylalkyl- a -hydroxyphenäthyl-amine, ihre Herstellung und diese enthaltende Arzneimittel |
-
1972
- 1972-06-09 FR FR7220746A patent/FR2187319B1/fr not_active Expired
-
1973
- 1973-06-06 BE BE2052823A patent/BE800510A/xx unknown
- 1973-06-07 CH CH825073A patent/CH573897A5/xx not_active IP Right Cessation
- 1973-06-08 DE DE19732329298 patent/DE2329298A1/de active Pending
- 1973-06-08 NL NL7308001A patent/NL7308001A/xx not_active Application Discontinuation
- 1973-06-08 GB GB2743173A patent/GB1395124A/en not_active Expired
- 1973-06-09 JP JP6529773A patent/JPS4969645A/ja active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003104178A1 (en) * | 2002-06-07 | 2003-12-18 | Cortical Pty Ltd | Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (mif) |
| GB2405146A (en) * | 2002-06-07 | 2005-02-23 | Cortical Pty Ltd | Napthalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (MIF) |
Also Published As
| Publication number | Publication date |
|---|---|
| NL7308001A (enrdf_load_stackoverflow) | 1973-12-11 |
| FR2187319B1 (enrdf_load_stackoverflow) | 1975-06-20 |
| JPS4969645A (enrdf_load_stackoverflow) | 1974-07-05 |
| FR2187319A1 (enrdf_load_stackoverflow) | 1974-01-18 |
| BE800510A (fr) | 1973-10-01 |
| GB1395124A (en) | 1975-05-21 |
| CH573897A5 (enrdf_load_stackoverflow) | 1976-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2203373C3 (de) | Neue 2- [(2- Alkylbenzofuran-3-yl)-methyl] -A2 -imidazoline | |
| DE1695556C3 (de) | 3-Alkyl-1,2,3,4,4a,9-hexahydropyrazino[1,2-f]morphanthridinderivate | |
| DE2557425A1 (de) | Chinazolonderivate | |
| DE2718669C2 (enrdf_load_stackoverflow) | ||
| DE2164058C3 (de) | Basisch substituierte Benzylphthalazinon-Derivate, ihre Salze, Verfahren zu ihrer Herstellung und diese Produkte enthaltende pharmazeutische Präparate | |
| DE2414273C3 (de) | N-Methyl-D-glucaminsalz von 2-(2'-Methyl-3'-trifluormethyl-anilin)-nicotinsäure, Verfahren zu seiner Herstellung und es enthaltende Arzneimittelzubereitung | |
| EP0105210B1 (de) | Isochinolinderivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate auf Basis dieser Verbindungen und ihre Verwendung | |
| DE2044172C3 (de) | Pyrrolderivate, ein Verfahren zu ihrer Herstellung und Arzneimittel | |
| DE3326724A1 (de) | In 1-stellung substituierte 4-hydroxymethyl-pyrrolidinone, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen und zwischenprodukte | |
| DE2749584A1 (de) | Ueberbrueckte geminale diphenylpiperidine, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
| DE2329298A1 (de) | Naphtalinderivate und deren anwendung als neue medikamente | |
| DE2513136C3 (de) | N-(1-Benzylpiperid-4-yl)-benzamide, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate | |
| DE2323005A1 (de) | Neue derivate des cumarons und deren verwendung als medikamente | |
| DE1470074A1 (de) | Hexahydro-11bH-benzo[a]chinolizine sowie Verfahren zu ihrer Herstellung | |
| DE2445002C2 (de) | N,N'-(Pyridin-diyl)-dioxamidsäurederivate und deren pharmazeutisch verträgliche Säureadditionssalze, Verfahren zu deren Herstellung und dieselben enthaltende pharmazeutische Mittel | |
| DE1937515C3 (de) | N-(2'-PyiToIidinylmelhyl)-2-methoxy-4-hydroxy-5-chlorbenzamide, deren Salze, Verfahren zu deren Herstellung und Arzneimittel | |
| DE2630764C2 (de) | N-Substituierte 3-Amino-3H-isobenzofuranone und diese Verbindungen enthaltende Arzneimittel | |
| DE2024389C3 (de) | 23 Dihydrobenzofuranderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE2029991C3 (de) | 2-Hydroxy-5-aminobenzamide, Verfahren zu ihrer Herstellung und Arzneimittel, die diese Verbindungen enthalten | |
| EP0003286A2 (de) | Ergopeptidalkaloid-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen | |
| DE1695785A1 (de) | Neue,substituierte 2-Aminomethylbenzofuranverbindungen und Verfahren zu deren Herstellung | |
| DE68909619T2 (de) | Wasserlösliche Salze der (+)2-(4-fluorphenyl)-alpha-methyl-5-benzoxazolessigsäure und deren Herstellung. | |
| DE3100516A1 (de) | Pyridylaminobenzoesaeuren, ihre herstellung und verwendung | |
| DE68907893T2 (de) | Neue 1,3,4,-thiadiazolderivate und antigeschwulstmittel, die diese enthalten. | |
| DE1618916C3 (de) | Aminoäther von 9,10-Äthano-9,10dihydroanthranolen-(9) und ihre Salze, Verfahren zu ihrer Herstellung, sowie diese Verbindungen enthaltende pharmazeutische Mittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OHJ | Non-payment of the annual fee |